Liminatus Pharma to Raise $2.4M via Stock and Warrant Offering
Ticker: LIMNW · Form: 8-K · Filed: Jul 3, 2025 · CIK: 1971387
| Field | Detail |
|---|---|
| Company | Liminatus Pharma, Inc. (LIMNW) |
| Form Type | 8-K |
| Filed Date | Jul 3, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: capital-raise, stock-offering, warrants
TL;DR
Liminatus Pharma raising $2.4M from stock/warrant sale, closing July 8th.
AI Summary
Liminatus Pharma, Inc. announced on July 2, 2025, that it has entered into a securities purchase agreement. The company plans to sell approximately 1.2 million shares of its common stock and warrants to purchase an equal number of shares at a combined price of $2.00 per share and accompanying warrant. The offering is expected to close on July 8, 2025, and is anticipated to raise gross proceeds of approximately $2.4 million before deducting offering expenses.
Why It Matters
This capital raise could provide Liminatus Pharma with crucial funding for its operations and potential growth initiatives, impacting its ability to advance its drug development pipeline.
Risk Assessment
Risk Level: medium — The company is raising capital through a stock and warrant offering, which can dilute existing shareholders and indicates a need for funding, potentially for ongoing operations or development.
Key Numbers
- $2.4M — Gross Proceeds (Anticipated funds to be raised from the securities purchase agreement.)
- 1.2M — Shares Offered (Number of common shares to be sold in the offering.)
- $2.00 — Per Unit Price (Combined price for one share of common stock and one warrant.)
- July 8, 2025 — Closing Date (Expected date for the completion of the securities purchase.)
Key Players & Entities
- Liminatus Pharma, Inc. (company) — Registrant
- July 2, 2025 (date) — Date of earliest event reported
- July 8, 2025 (date) — Expected closing date of the offering
- approximately $2.4 million (dollar_amount) — Anticipated gross proceeds from the offering
- approximately 1.2 million shares (share_amount) — Number of shares to be sold
- $2.00 (dollar_amount) — Combined price per share and accompanying warrant
FAQ
What is the purpose of the securities purchase agreement?
The company entered into the agreement to sell shares of its common stock and warrants, likely to raise capital for its operations and strategic initiatives.
How many shares and warrants is Liminatus Pharma selling?
Liminatus Pharma is selling approximately 1.2 million shares of its common stock and warrants to purchase an equal number of shares.
What is the price per unit for the offering?
The combined price for one share of common stock and one accompanying warrant is $2.00.
When is the offering expected to close?
The offering is expected to close on July 8, 2025.
What are the anticipated gross proceeds from this offering?
The company anticipates raising approximately $2.4 million in gross proceeds before deducting offering expenses.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 3, 2025 regarding Liminatus Pharma, Inc. (LIMNW).